R 1499Alternative Names: R1499
Latest Information Update: 14 Mar 2006
At a glance
- Originator Roche
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 13 Dec 2004 Phase-I clinical trials in Type-2 diabetes mellitus in Switzerland (unspecified route)
- 06 Aug 2003 Preclinical trials in Type-2 diabetes mellitus in Switzerland (unspecified route)